A Phase I/IIa Clinical Trial of a Humanised Monoclonal Antibody Against LRG1

LRG1人源化单克隆抗体I/IIa期临床试验

• 批准号: MR/N006410/1
• 负责人: Stephen Moss
• 金额: $ 722万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FN006410%2F1
• 关键词: Phase; IIa; Clinical; Trial; Humanised

The aim of this proposal is to conduct a Phase I/IIa clinical trial of a new drug targeting a secreted protein named leucine-rich alpha-2 glycoprotein 1 (LRG1). Our group discovered LRG1 a few years ago in a search for new therapeutic targets in retinal vascular disease. We showed that LRG1 stimulates abnormal blood vessel growth in the eye, and demonstrated using a variety of experimental strategies that pathological angiogenesis (new blood vessel growth) can be prevented by inhibiting LRG1. This led us to speculate that we could target LRG1 in retinal vascular disease by using a function-blocking monoclonal antibody directed against this protein.With support from a MRC DPFS award we recently completed the development of Magacizumab, a fully humanized de-immunised function-blocking monoclonal antibody against LRG1. The humanisation of the antibody prevents its rejection by the patients' immune system. This antibody has high affinity and specificity for LRG1, and in a mouse model of "wet" age-related macular degeneration (AMD) we established that the antibody is as effective as the current standard of care (SOC), Eylea, in preventing lesion formation. Moreover, unlike current SOC our therapy targets a different angiogenic pathway and as such may provide greater benefit when administered either alone or in combination. Based on these proof of concept observations we designed the LABINA trial, a first in man examination of the humanized LRG1 antibody, in patients with the 'wet' form of AMD.The LABINA trial comprises two parts. In Phase I we will perform a dose-escalation study in which individual patients are given increasing doses of Magacizumab in order to establish safety of the therapy and the maximum tolerated dose. In Phase IIa we will administer Magacizumab in combination with SOC, with a control group of patients receiving SOC alone plus sham injection. Although the primary endpoint of the trial is safety and tolerability, we have designed the study so as to maximize the chances of seeing clinical benefit.A successful outcome to the LABINA trial will pave the way for larger scale trials and onward commercialization. We have a strong position with regard to intellectual property, and given the substantial economic potential of antibody therapies plus the scope for application in other clinical indications, such as cancer, we are confident of finding either a pharmaceutical partner or investors to support a spin-out company.

这项提议的目的是进行一种新药的I/IIa期临床试验，该新药针对一种名为富含亮氨酸的α-2糖蛋白1(LRG1)的分泌蛋白。我们小组几年前在寻找视网膜血管疾病的新治疗靶点时发现了LRG1。我们证明了LRG1刺激眼睛中异常的血管生长，并使用各种实验策略证明可以通过抑制LRG1来防止病理性血管生成(新血管生长)。这使我们推测，我们可以通过使用针对这种蛋白的功能阻断单抗来靶向视网膜血管疾病中的LRG1。在MRC DPFS奖的支持下，我们最近完成了Magacizumab的开发，这是一种完全人源化的去免疫的针对LRG1的功能阻断单抗。抗体的人源化防止了患者免疫系统的排斥反应。这种抗体对LRG1具有高亲和力和特异性，在“湿性”老年性黄斑变性(AMD)的小鼠模型中，我们证实该抗体在防止病变形成方面与当前的护理标准(SOC)Eylea一样有效。此外，与目前的SOC不同，我们的治疗针对的是不同的血管生成途径，因此当单独或联合应用时，可能会提供更大的好处。基于这些概念验证观察，我们设计了LABINA试验，这是对人源化LRG1抗体的第一次人内检查，用于“湿”形式的AMD。LABINA试验包括两个部分。在第一阶段，我们将进行剂量递增研究，给个别患者递增剂量的Magacizumab，以确定治疗的安全性和最大耐受量。在IIa期，我们将联合应用Magacizumab和SOC，并将对照组患者仅接受SOC和假注射。虽然试验的主要终点是安全性和耐受性，但我们设计这项研究是为了最大限度地增加临床受益的机会。LABINA试验的成功结果将为更大规模的试验和进一步的商业化铺平道路。我们在知识产权方面拥有强大的地位，考虑到抗体疗法的巨大经济潜力以及在其他临床适应症(如癌症)中的应用范围，我们有信心找到制药合作伙伴或投资者来支持一家衍生公司。

项目成果

Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis.

• DOI: 10.1126/scitranslmed.abe6805
• 发表时间: 2021-09
• 期刊: Science translational medicine
• 影响因子: 17.1
• 作者: Singhal M;Gengenbacher N;Abdul Pari AA;Kamiyama M;Hai L;Kuhn BJ;Kallenberg DM;Kulkarni SR;Camilli C;Preuß SF;Leuchs B;Mogler C;Espinet E;Besemfelder E;Heide D;Heikenwalder M;Sprick MR;Trumpp A;Krijgsveld J;Schlesner M;Hu J;Moss SE;Greenwood J;Augustin HG
• 通讯作者: Augustin HG

LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency.

• DOI: 10.1016/j.medj.2021.10.002
• 发表时间: 2021-11-12
• 期刊: Med (New York, N.Y.)
• 作者: O'Connor MN;Kallenberg DM;Camilli C;Pilotti C;Dritsoula A;Jackstadt R;Bowers CE;Watson HA;Alatsatianos M;Ohme J;Dowsett L;George J;Blackburn JWD;Wang X;Singhal M;Augustin HG;Ager A;Sansom OJ;Moss SE;Greenwood J
• 通讯作者: Greenwood J